PYC Therapeutics LimitedASX: PYC

PKD Program - Presentation of Data at ASN Conference

· Issued by PYC Therapeutics Limited

Filed with ASX · · 5 pages · English

Summary by 6ix AI

PYC Therapeutics Limited announces the presentation of exploratory efficacy data from its Polycystic Kidney Disease program at the upcoming ASN conference. The company emphasizes that these findings are preliminary and require further validation in larger studies before drawing definitive conclusions about the drug's impact on the disease.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/pkd-program-presentation-of-data-at-asn-conference

Release

pyctx.com | ACN 098 391 961 1 7 October 2026 POLYCYSTIC KIDNEY DISEASE PROGRAM – PRESENTATION OF DATA AT ASN CONFERENCE • PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available • The Company is...

PYC Therapeutics Limited on 6ix

Story so far

Earlier from PYC Therapeutics

All PYC Therapeutics news releases